Literature DB >> 12973674

3p21, 5q21, 9p21 and 17p13 allelic deletions accumulate in the dysplastic spectrum of laryngeal carcinogenesis and precede malignant transformation.

J Sanz-Ortega1, C Valor, M C Saez, L Ortega, E Sierra, J Poch, S Hernández, J Sanz-Esponera.   

Abstract

A tissue field of somatic genetic alterations precede the histopathological phenotypic changes of carcinoma. Loss of Heterozygosity (LOH) at the sites of known or putative tumor suppressor genes is a common genetic abnormality detected in precancerous conditions. These genomic changes could be of potential use in the diagnosis and prognosis of pre-malignant laryngeal lesions. Recently the concept of laryngeal intraepithelial neoplasia (LIN) was introduced. To evaluate patients with an increased risk of developing invasive laryngeal carcinoma via a dysplasia-carcinoma progression we investigated 102 microdissected cell populations. Cell populations were procured from 15 laryngectomy specimens with different peritumoral histological changes adjacent to the squamous cell carcinoma cells and 15 laryngeal endoscopic biopsies with no evidence of malignant transformation in a 6-10-year follow-up period. Histological diagnoses were subdivided into keratosis without dysplasia (KWD), with mild dysplasia (LIN 1), with moderate dysplasia (LIN 2), and with severe dysplasia or carcinoma in situ (LIN 3). Microsatellite analysis was performed with the aim of studying LOH of 5q21 (APC), 9p21 (p16), 3p21 and 17p13 (p53) chromosomal regions. Frequent allelic losses were found in carcinoma cells at p53 (54%), p16 (66%), 3p21(87%) and 5q21(58%). Identical LOH patterns were determined in 100% of the LIN3 peritumoral cells, 60% of LIN2, 50% of LIN 1 and 25% of KWD. In contrast, histologically normal mucosae, KWD and LIN1 lesions without malignant progression showed no allelic loss. These results show that dysplasia correlates with LOH at 3p21, 5q21, 9p21 and 17p13 in early laryngeal carcinogenesis. These genomic changes in pre-malignant laryngeal lesions could be of potential use as markers for cancer risk assessment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973674     DOI: 10.14670/HH-18.1053

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  7 in total

1.  The impact of laryngeal dysplasia on the development of laryngeal squamous cell carcinoma.

Authors:  J C Luers; K Sircar; U Drebber; D Beutner
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-30       Impact factor: 2.503

2.  Possible implication of Mdm2 as a prognostic marker in invasive laryngeal carcinoma.

Authors:  Marcela K Hassumi-Fukasawa; Fabiana A Miranda-Camargo; Márcia C M Guimarães; Renata T Simões; Eduardo A Donadi; Christiane P Soares; Edson G Soares
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-02-05       Impact factor: 2.503

Review 3.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

4.  Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology.

Authors:  Matthias Woenckhaus; Ulrike Grepmeier; Bernhard Werner; Christian Schulz; Felix Rockmann; Peter J Wild; Georg Röckelein; Hagen Blaszyk; Marion Schuierer; Ferdinand Hofstaedter; Arndt Hartmann; Wolfgang Dietmaier
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

5.  Promoter methylation in head and neck tumorigenesis.

Authors:  Josena K Stephen; Kang Mei Chen; Shaleta Havard; Glynis Harris; Maria J Worsham
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma.

Authors:  Jarrett E Walsh; Deanne M R Lathers; Angela C Chi; M Boyd Gillespie; Terry A Day; M Rita I Young
Journal:  Curr Treat Options Oncol       Date:  2007-06

7.  OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome.

Authors:  S Staibano; F Merolla; D Testa; R Iovine; M Mascolo; V Guarino; M D Castellone; M Di Benedetto; V Galli; S Motta; R M Melillo; G De Rosa; M Santoro; A Celetti
Journal:  Br J Cancer       Date:  2007-11-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.